Pharmaceutical Executive-01-01-2004

Pharmaceutical Executive
Features

January 01, 2004

New rules of engagement can help pharma companies to overcome the paralysis of creative conflict.

Pharmaceutical Executive

In spite of pharmaceutical employers' best intentions to the contrary, sales rep compensation is being squeezed in a vise that is gradually narrowing the gaps between what top, average, and bottom performers are earning. According to the Hay Group's Pharmaceutical Sales Force Effectiveness Study, co-sponsored by Pharmaceutical Executive, reps in the 90th percentile are earning just 40 percent more than the average performer. This is not to suggest that reps aren't being paid handsomely (they are), but that the pay-for-performance model is showing signs of weakness.

Pharmaceutical Executive

In PE's December Pipeline Report, an unexpected Phase III candidate rose to the top. The drug: BioMarin's Aryplase. The reason for its success: an amazing turnaround job by chairman and CEO Fred Price. But Aryplase is not Price's first accomplishment at BioMarin, which was spun off from Glyko BioMedical in 1997. It is, in fact, only one of many that resulted from Price's efforts to jump-start a stalled company.

Pharmaceutical Executive
Features

January 01, 2004

Think back: When did you first hear the phrase metabolic syndrome? When did it start to become part of your business and its plans?

Pharmaceutical Executive

January 01, 2004

Table of Contents